Editas Medicine Inc
NASDAQ:EDIT

Watchlist Manager
Editas Medicine Inc Logo
Editas Medicine Inc
NASDAQ:EDIT
Watchlist
Price: 2.88 USD -5.88% Market Closed
Market Cap: 241.1m USD
Have any thoughts about
Editas Medicine Inc?
Write Note

Wall Street
Price Targets

EDIT Price Targets Summary
Editas Medicine Inc

Wall Street analysts forecast EDIT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EDIT is 3.44 USD with a low forecast of 1.01 USD and a high forecast of 5.25 USD.

Lowest
Price Target
1.01 USD
65% Downside
Average
Price Target
3.44 USD
20% Upside
Highest
Price Target
5.25 USD
82% Upside
Editas Medicine Inc Competitors:
Price Targets
CDNA
CareDx Inc
45% Upside
4593
Healios KK
9% Downside
000403
Pacific Shuanglin Bio pharmacy Co Ltd
21% Upside
VITR
Vitrolife AB
50% Upside
600161
Beijing Tiantan Biological Products Corp Ltd
53% Upside
068270
Celltrion Inc
23% Upside
302440
SK Bioscience Co Ltd
17% Downside
2696
Shanghai Henlius Biotech Inc
32% Downside

Revenue
Forecast

Revenue Estimate
Editas Medicine Inc

For the last 8 years the compound annual growth rate for Editas Medicine Inc's revenue is 23%. The projected CAGR for the next 3 years is -19%.

23%
Past Growth
-19%
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Editas Medicine Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat

Net Income
Forecast

Net Income Estimate
Editas Medicine Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-23%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is EDIT's stock price target?
Price Target
3.44 USD

According to Wall Street analysts, the average 1-year price target for EDIT is 3.44 USD with a low forecast of 1.01 USD and a high forecast of 5.25 USD.

What is Editas Medicine Inc's Revenue forecast?
Projected CAGR
-19%

For the last 8 years the compound annual growth rate for Editas Medicine Inc's revenue is 23%. The projected CAGR for the next 3 years is -19%.

Back to Top